Vaccine formulations including preservative systems
By using 0.1% to 0.6% of 2-phenoxyethanol in vaccine preparations and the problem of insufficient antibacterial effect of thimerosal is solved, effectively preventing microorganisms and viruses. Ensure the stability and safety of the vaccine.
Patent Information
- Application Number
- CN201980048765.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-07-21
- Filing Date
- 2019-07-19
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2039-07-19
AI Technical Summary
Thimerosal used in existing vaccine preparations as preservatives has safety and environmental problems, and 2-phenoxyethanol (2-PE) is insufficient in antibacterial effect at low concentrations, making it difficult to effectively prevent the growth of microorganisms and viruses.
A preservative system was developed that contains 0.1% to 0.6% of 2-phenoxyethanol in combination with other preservatives such as m-cresol, benzyl alcohol, phenol and benzoic acid for use in vaccine formulations to prevent microorganisms and viruses. Grow.
The preservative system significantly and effectively prevents the growth of microorganisms and viruses at low concentrations, ensures the stability and safety of the vaccine, meets pharmacopoeia standards, and does not have a negative impact on the immunogenicity of the vaccine.
Smart Images

Figure BDA0002909020170000152 
Figure BDA0002909020170000161 
Figure BDA0002909020170000162
Abstract
Description
Technical Field
[0001] The present invention relates to a preservative system and its use in a vaccine formulation. More particularly, the present invention relates to a monovalent or multivalent vaccine formulation comprising a preservative system and which does not contain thimerosal. Background Art
[0002] Vaccines are biological preparations that provide active acquired immunity against a specific disease. Vaccines typically contain an agent similar to the pathogenic microorganism and are usually made from an attenuated or killed form of the microorganism, its toxins or at least one of its surface proteins or at least one of its capsular polysaccharides. The agent stimulates the body's immune system to recognize the agent as a threat, destroy it, and recognize and destroy any of these microorganisms it subsequently encounters. In addition to having a certain level of immunogenicity, efficacy, stability, vaccine formulations also need to be free from microbial contamination.
[0003] Multidose vaccine formulations require preservatives to prevent contamination and stabilize the composition of subsequent doses after the first dose has been used. Preservatives are necessary to enable the vaccine formulation to pass efficacy testing or testing against microbial challenge.
[0004] U.S. Patent No. 6,790,445 B1 discloses a preservative combination that passes the antimicrobial test requirements of the United States Pharmacopoeia (USP), the British Pharmacopoeia (BP) and the European Pharmacopoeia (EP), which is selected from the group consisting of (1) 1.5% benzyl alcohol, (2) 0.225% sodium methylparaben, 0.025% sodium propylparaben and 0.9% benzyl alcohol and (3) 0.225% sodium methylparaben, 0.025% sodium propylparaben and 0.375% 2-phenoxyethanol.
[0005] U.S. Patent No. 9,095,567 B2 describes a multivalent immunogenic composition comprising a single conjugated to a CRM 197 The invention relates to a polysaccharide-protein conjugate composed of pneumococcal capsular polysaccharides of Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F, and further comprises 2-phenoxyethanol (2-PE) of not less than 7 mg / mL. The patent discloses that the results of the preservative efficacy test (PET) show that all the preservatives tested meet the USP requirements but do not meet the EP standards. 2-PE is the only candidate preservative that has been found to be safe at higher doses.
[0006] US Patent Publication No. 2004 / 0258700 A1 discloses a vaccine formulation comprising an immunogen and a preservative, wherein the preservative is a combination of at least two parabens and 2-phenoxyethanol.
[0007] U.S. Patent Publication No. 2013 / 0273098 A1 describes the addition of 0.1% poloxamer 188 ( F-68) resulted in no observation of particles with any of the tested preservatives such as phenol, 2-phenoxyethanol, m-cresol, benzyl alcohol or chlorobutanol.
[0008] WO Publication No. 2018 / 169303A1 discloses a vaccine composition comprising: (i) a capsular polysaccharide-protein conjugate; (ii) 2-phenoxyethanol (2-PE); and (iii) formaldehyde (HCHO), and a method for preparing the same.
[0009] Hilliard et al. (1964, Journal of Pharmaceutical Sciences 53(8), 899-901) disclosed the addition of 0.375 percent v / v of 2-phenoxyethanol to polio vaccine to provide a stable preservative (streptomycin, neomycin and 2-phenoxyethanol) mixture that was inhibitory to both bacteria and fungi.
[0010] Stephen et al. (1985, International Journal of Pharmaceutics, 25, 245-253) disclose that antimicrobial preservatives belonging to the same chemical group are believed to have only an additive effect when used in combination.
[0011] Preservatives generally provide limited protection against viral contamination. For example, bactericides and fungicides can cause their effects on various microbial cell targets, such as the cell wall, cytoplasmic membrane, or cytoplasm. It is often difficult to specify a precise target for a particular class of preservatives; the target can and does vary with preservative concentration. Therefore, preservatives often interfere with several different microbial cell mechanisms. This cytotoxicity can also affect mammalian cells. Therefore, the level of internalization should be minimized and consistent with appropriate preservation. Regulatory authorities expect detailed information on the reasons for preservative internalization, proof of efficacy, safety information, control methods, and labeling in the final product.
[0012] In concept, a preservative system protects the product against microbial growth without impairing product performance. In practice, this means that it must:
[0013] ·Exerts broad-spectrum antimicrobial activity at low internalization levels.
[0014] Maintain activity during product manufacturing, shelf life and use.
[0015] ·Do not compromise the quality or performance of the product, packaging or delivery system.
[0016] Do not adversely affect patient safety or product tolerability.
[0017] The pharmacopoeial Antimicrobial Efficacy Test (AET) or Preservative Efficacy Test (PET) involves challenging the product with a defined number of colony forming units (cfu) of various test microorganisms (bacteria, yeasts and fungi), counting at time zero, and then monitoring the kill / survival at defined time intervals. In addition to the Antimicrobial Efficacy Test (AET), the regulatory requirement is to monitor the chemical stability of the drug product (in its final container) throughout the product's proposed shelf life.
[0018] Thimerosal (also known as thimerosal; mercaptide) is an ethylmercury-containing preservative that has been added to many multi-dose injectable formulations since the early 1930s. Thimerosal, which contains mercury, has been reported to cause autism in children and is toxic to the environment. It would be advantageous to find a preservative that is safe for vaccines to replace thimerosal. Therefore, there is a need for vaccine formulations that include safe and effective preservatives.
[0019] Although 2-phenoxyethanol (2-PE) has a better safety profile than mercuric preservatives (eg, thimerosal), it is the weaker antimicrobial of the two and needs to be included in vaccine formulations at higher concentration levels.
[0020] Therefore, in order to improve the preservative efficacy of 2-PE at low concentration levels in vaccine formulations, the inventors of the present invention have developed a low-concentration preservative system comprising 2-PE in combination with other preservatives through their continuous efforts. The inventors have found that the preservative system is safe and effective for preventing the growth of microorganisms / viruses in vaccine formulations.
[0021] Purpose of the invention
[0022] An object of the present invention is to provide a preservative composition comprising 2-phenoxyethanol at low concentration levels for use in vaccine formulations for preventing microbial / viral growth.
[0023] Another object of the present invention is to provide a stable multi-dose vaccine formulation comprising low concentration levels of 2-phenoxyethanol. Summary of the invention
[0024] Thus, the present invention provides a vaccine formulation comprising a preservative system comprising 2-phenoxyethanol at a concentration in the range of 0.1% to 0.6% and at least one other preservative selected from the group consisting of m-cresol, benzyl alcohol, phenol and benzoic acid.
[0025] The present invention also provides a vaccine formulation comprising an immunogen, a preservative system comprising 2-phenoxyethanol at a concentration in the range of 0.1% to 0.6% and at least one other preservative selected from the group consisting of m-cresol, benzyl alcohol, phenol and benzoic acid, and one or more suitable pharmaceutically acceptable excipients.
[0026] The present invention also provides a method for manufacturing a vaccine formulation comprising a preservative system comprising 2-phenoxyethanol at a concentration in the range of 0.1% to 0.6% and at least one other preservative selected from the group consisting of m-cresol, benzyl alcohol, phenol and benzoic acid.
[0027] The present invention also provides a method for manufacturing a vaccine formulation comprising a preservative system comprising 2-phenoxyethanol at a concentration in the range of 0.1% to 0.5% and at least one other preservative selected from the group consisting of at least 0.005% of m-cresol, benzyl alcohol, phenol and benzoic acid. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1 A graphical layout depicting serum antibody titers in rabbits.
[0029] Figure 2A &B depicts serum antibody titers in rabbits immunized with a preservative-free formulation (Example 2).
[0030] Figure 3A &B depicts serum antibody titers in rabbits immunized with a formulation containing a preservative system (Example 3). DETAILED DESCRIPTION
[0031] By referring to the following detailed description, examples and drawings, the embodiments described herein can be more easily understood. The elements, devices and methods described herein are merely illustrations of the principles of the invention and are not limited to the specific embodiments presented in the detailed description, examples and drawings. Many improvements and adaptations will be apparent to those skilled in the art without departing from the spirit and scope of the invention.
[0032] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the methods belong. Although any combinations, compositions or methods similar or equivalent to those described herein can also be used in the practice or testing of embodiments of the present invention, representative illustrative methods and compositions are now described.
[0033] It should be understood that certain features of the methods described in the context of separate embodiments for the sake of clarity may also be provided in combination in a single embodiment. Conversely, for the sake of brevity, the various features of the methods and compositions described in the context of a single embodiment may also be provided separately or in any suitable sub-combination. Note that, as used herein and in the appended claims, the singular forms "one", "a kind" and "the" include plural indicators unless the context clearly indicates otherwise. It should also be noted that the claims may be written to exclude any optional elements. As such, this statement is intended to serve as a prior basis for the use of such exclusive terms as "single", "only" or "negative" restrictions in conjunction with the detailed description of the claim elements. The term "at least one / kind" refers to one / kind or more than one / kind.
[0034] It will be apparent to those skilled in the art after reading this disclosure that each individual embodiment described and illustrated herein has discrete components and features that can be readily separated or combined with the features of any other embodiment without departing from the scope or spirit of the present method. Any described method can be carried out in the order of events described or in any other order that is logically possible.
[0035] As used herein, the terms "preservative system" or "preservative composition" are interchangeable and refer to a mixture or composition added to a vaccine composition or formulation to prevent decomposition due to chemical changes or microbial / viral contamination. In the context of the present invention, a preservative system refers to a composition comprising 2-phenoxyethanol and at least one other preservative selected from the group consisting of m-cresol, benzyl alcohol, phenol and benzoic acid.
[0036] The term "immunogen or antigen" refers to a substance that stimulates the production of antibodies or elicits a humoral and / or cellular immune response, thereby resulting in immunization of the host against a pathogen.
[0037] As used herein, the term "monovalent vaccine" refers to a vaccine having one major antigenic component.
[0038] As used herein, the term "multivalent vaccine" refers to a vaccine that includes more than one antigenic component. The term includes combination vaccines, bivalent vaccines, trivalent vaccines, quadrivalent vaccines, pentavalent vaccines, hexavalent vaccines, etc.
[0039] As used herein, the term "Vi:02" refers to a bivalent vaccine formulation against typhoid and paratyphoid that includes antigens from Salmonella typhi and Salmonella paratyphi.
[0040] As used herein, the term "MR" refers to a bivalent vaccine formulation against measles and rubella.
[0041] As used herein, the term "Td" refers to diphtheria and tetanus vaccine [adsorbed, reduced antigen content].
[0042] As used herein, the term "DTwP" refers to a trivalent vaccine formulation against diphtheria, tetanus and whole cell pertussis.
[0043] As used herein, the term "Vi:O2-HepA" refers to a trivalent vaccine formulation against typhoid, paratyphoid and hepatitis A.
[0044] As used herein, the term "MMR" refers to a trivalent vaccine formulation against measles, mumps, and rubella.
[0045] As used herein, the term "DTwP-Hib" refers to a quadrivalent vaccine formulation against diphtheria, tetanus, whole cell pertussis and Haemophilus influenzae type b.
[0046] As used herein, the term "DTaP-Hib" refers to a quadrivalent vaccine formulation against diphtheria, tetanus, acellular pertussis and Haemophilus influenzae type b.
[0047] As used herein, the term "DTwP-IPV" refers to a quadrivalent vaccine formulation against diphtheria, tetanus, whole cell pertussis, and inactivated polioviruses.
[0048] As used herein, the term "DTwP-HepB" refers to a quadrivalent vaccine formulation against diphtheria, tetanus, whole cell pertussis and hepatitis B.
[0049] As used herein, the term "ACW-135XY" refers to a pentavalent conjugate vaccine formulation against meningococcal groups A, C, W-135, X, and Y.
[0050] As used herein, the term "DtwPHib-HepB" refers to a pentavalent vaccine formulation against diphtheria, tetanus, whole cell pertussis, Haemophilus influenzae type b, and hepatitis B.
[0051] As used herein, the term "DtaPHib-HepB" refers to a pentavalent vaccine formulation against diphtheria, tetanus, acellular pertussis, Haemophilus influenzae type b and hepatitis B.
[0052] As used herein, the term "DtwPHib-HepB-IPV" refers to a hexavalent vaccine formulation against diphtheria, tetanus, whole cell pertussis, Haemophilus influenzae type b, hepatitis B, and inactivated poliovirus.
[0053] As used herein, the term "DtaPHib-HepB-IPV" refers to a hexavalent vaccine formulation against diphtheria, tetanus, acellular pertussis, Haemophilus influenzae type b, hepatitis B, and inactivated poliovirus.
[0054] As used herein, the term "pharmaceutically acceptable carrier" refers to one or more optional components that can be added to a vaccine formulation for administering an antigen and / or virus, which itself does not induce the production of antibodies harmful to the individual receiving the composition, and can be administered without excessive toxicity. The term includes one or more excipients, adjuvants, diluents, buffers or surfactants or combinations thereof. Pharmaceutically acceptable or pharmacologically acceptable refers to a material that is not biologically or otherwise undesirable, i.e., the material can be administered to an individual in a formulation or composition without causing any undesirable biological effects or interacting in a harmful manner with the components of any composition containing it.
[0055] As used herein, the phrase "microbial or viral contamination" refers to the unwanted growth of microorganisms or viruses in a vaccine formulation. DETAILED DESCRIPTION OF THE INVENTION
[0057] As used herein, vaccines or immunogens of the invention include pneumococcal conjugates, meningococcal conjugates, typhoid conjugates, paratyphoid conjugates, Hib conjugates and multivalent vaccines comprising one or more antigens selected from measles (M), mumps (M), rubella (R), hepatitis A virus (HAV), hepatitis C virus (HCV), diphtheria (D), tetanus (T), whole cell (wP) or acellular pertussis (aP), Hib polysaccharide, hepatitis B (HepB) and inactivated poliovirus (IPV).
[0058] Monovalent vaccines include those selected from or isolated from Streptococcus pneumonia (pneumococcal capsular polysaccharide), Neisseria meningitides (Men A, C, W-135 or Y), Salmonella typhi (Vi), Salmonella paratyphi (O:2), Haemophilus influenza (Hib-PRP), Corynebacterium Diptheriae (diphtheria toxoid-DT), Bordetella pertussis (wP / aP), Clostridium tetani (tetanus toxoid), hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), inactivated Japanese encephalitis virus (Japanese Encephalitis virus, rabies virus and inactivated poliomyelitis virus antigens.
[0059] Multivalent vaccines include bivalent, trivalent, quadrivalent, pentavalent and hexavalent vaccines, such as DT (diphtheria toxoid), MR (measles and rubella vaccine), Vi:O2 (Salmonella typhi and Salmonella paratyphi) conjugate, Vi:O2-HepA (Salmonella typhi, Salmonella paratyphi and hepatitis A vaccine), MMR (measles, mumps and rubella vaccine), DTwP vaccine (vaccine against diphtheria, tetanus and whole cell pertussis), ACW-135XY (conjugate vaccine against meningococcal groups A, C, W-135, X and Y), DTwP-Hib (vaccine against diphtheria, tetanus, whole cell pertussis and Haemophilus influenzae type b), DTaP-Hib (vaccine against diphtheria, tetanus, acellular pertussis and Haemophilus influenzae type b), DTwP-HepB (vaccine against diphtheria, tetanus, acellular pertussis and Haemophilus influenzae type b), and ACW-135XY (vaccine against meningococcal groups A, C, W-135, X and Y). dtwPHib-HepB (vaccine against diphtheria, tetanus, whole-cell pertussis, Haemophilus influenzae type b, and hepatitis B), dtwPHib-HepB (vaccine against diphtheria, tetanus, whole-cell pertussis, Haemophilus influenzae type b, and hepatitis B), dtwP-IPV (vaccine against diphtheria, tetanus, whole-cell pertussis, Haemophilus influenzae type b, and hepatitis B), dtwPHib-HepB-IPV (vaccine against diphtheria, tetanus, whole-cell pertussis, Haemophilus influenzae type b, and hepatitis B), dtwPHib-HepB-IPV (vaccine against diphtheria, tetanus, non-cellular pertussis, Haemophilus influenzae type b, hepatitis B, and inactivated poliovirus).
[0060] As used herein, concentration percentages (%) are by volume (w / v) or by weight (w / w).
[0061] The present invention provides monovalent and multivalent combination vaccine formulations comprising a preservative system comprising 2-phenoxyethanol at a concentration in the range of 0.1% to 0.6% and at least one other preservative selected from the group consisting of m-cresol, benzyl alcohol, phenol and benzoic acid.
[0062] In an embodiment, the present invention provides a pneumococcal capsular polysaccharide protein conjugate vaccine formulation comprising one or more pneumococcal polysaccharide protein conjugates and a preservative system comprising 2-phenoxyethanol at a concentration in the range of 0.1% to 0.6% and at least one other preservative selected from the group consisting of m-cresol, benzyl alcohol, phenol and benzoic acid and one or more pharmaceutically acceptable carriers or excipients.
[0063] In yet another embodiment, the present invention provides a meningococcal conjugate vaccine formulation comprising Neisseria meningitidis serogroups A, C, W-135, X and Y capsular polysaccharide antigens individually conjugated to a carrier protein and a preservative system comprising 2-phenoxyethanol at a concentration in the range of 0.1% to 0.6% and at least one other preservative selected from the group consisting of m-cresol, benzyl alcohol, phenol and benzoic acid and one or more pharmaceutically acceptable carriers or excipients.
[0064] In still another embodiment, the present invention provides a typhoid conjugate vaccine formulation comprising a Vi polysaccharide conjugated to a carrier protein and a preservative system comprising 2-phenoxyethanol at a concentration in the range of 0.1% to 0.6% and at least one other preservative selected from the group consisting of m-cresol, benzyl alcohol, phenol and benzoic acid and one or more pharmaceutically acceptable carriers or excipients.
[0065] In still another embodiment, the present invention provides a paratyphoid conjugate vaccine formulation comprising an O:2 polysaccharide conjugated to a carrier protein and a preservative system comprising 2-phenoxyethanol at a concentration in the range of 0.1% to 0.6% and at least one other preservative selected from the group consisting of m-cresol, benzyl alcohol, phenol and benzoic acid and one or more pharmaceutically acceptable carriers or excipients.
[0066] In yet another embodiment, the present invention provides a HIb conjugate vaccine formulation comprising a polyribosylribitol phosphate (PRP) capsular polysaccharide conjugated to a carrier protein and a preservative system comprising 2-phenoxyethanol at a concentration in the range of 0.1% to 0.6% and at least one other preservative selected from the group consisting of m-cresol, benzyl alcohol, phenol and benzoic acid and one or more pharmaceutically acceptable carriers or excipients.
[0067] In an embodiment, the present invention provides a pneumococcal capsular polysaccharide protein conjugate vaccine formulation comprising one or more pneumococcal polysaccharide protein conjugates and a preservative system comprising 2-phenoxyethanol at a concentration of 0.1% to 0.6% and at least one other preservative selected from the group consisting of m-cresol, benzyl alcohol, phenol and benzoic acid at a concentration of 0.005% to 0.3% and one or more pharmaceutically acceptable carriers.
[0068] The carrier protein according to the present invention is selected from the group consisting of CRM 197 , PspA, PsaA, protein D, diphtheria toxoid (DT), tetanus toxoid (TT), etc. or a combination thereof.
[0069] The pneumococcal conjugate vaccine according to the invention comprises one or more capsular polysaccharides from a serotype of S. pneumoniae selected from serotypes 1, 2, 3, 4, 5, 6A, 6B, 6C, 6D, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15A, 15B, 15C, 16F, 17F, 18C, 19F, 19A, 20A, 20B, 22F, 23A, 23B, 23F, 24B, 24F, 31, 33F, 34, 35B, 35F, 38, 39 and 45 of S. pneumoniae, wherein each polysaccharide is conjugated to a carrier protein, which is preferably selected from PsaA, CRM 197 , inactivated bacterial toxins such as diphtheria toxoid (DT), tetanus toxoid (TT), pertussis toxoid, cholera toxoid or Haemophilus influenzae protein D or a combination thereof; and a preservative system comprising 2-phenoxyethanol at a concentration in the range of 0.1% to 0.6% and at least one other preservative selected from the group consisting of m-cresol, benzyl alcohol, phenol, benzoic acid, and one or more pharmaceutically acceptable carriers.
[0070] In an embodiment, the invention provides a pneumococcal conjugate vaccine formulation comprising pneumococcal capsular polysaccharides conjugated to a carrier protein, wherein each polysaccharide is selected from S. pneumoniae serotypes 1, 2, 3, 4, 5, 6A, 6B, 6C, 6D, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15A, 15B, 15C, 16F, 17F, 18C, 19F, 19A, 20A, 20B, 22F, 23A, 23B, 23F, 24B, 24F, 31, 33F, 34, 35B, 35F, 38, 39 and 45; and a preservative system comprising 2-phenoxyethanol at a concentration in the range of 0.1% to 0.6% and at least one other preservative selected from the group consisting of m-cresol, benzyl alcohol, phenol and benzoic acid.
[0071] In an embodiment, the invention provides a pneumococcal conjugate vaccine formulation comprising a pneumococcal capsular polysaccharide conjugated to a carrier protein, wherein each polysaccharide is selected from the group consisting of Streptococcus pneumoniae serotypes 1, 2, 3, 4, 5, 6A, 6B, 6C, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15A, 15B, 15C, 16F, 17F, 18C, 19F, 19A, 20A, 20B, 22F, 23A, 23B, 23F, 24B, 24F, 31, 33F, 34, 35B, 35F, 38, 39 and 45; and a preservative system comprising 2-phenoxyethanol at a concentration in the range of 0.1% to 0.6% and at least one other preservative selected from the group consisting of 0.005% to 0.3% m-cresol, 0.01% to 1% benzyl alcohol, 0.01% to 1% benzoic acid by weight of the vaccine formulation.
[0072] The pneumococcal capsular polysaccharide-protein conjugate vaccine according to the present invention is a multivalent immunogenic composition, such as a 10-valent, 13-valent, 14-valent, 15-valent, 16-valent, 17-valent, 18-valent, 19-valent, 20-valent, 22-valent, 23-valent, 24-valent, 25-valent or 26-valent pneumococcal vaccine composition.
[0073] In an embodiment, the pneumococcal capsular polysaccharide protein conjugate vaccine according to the invention is a 14-valent immunogenic composition comprising capsular polysaccharides from S. pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F.
[0074] In yet another embodiment, the pneumococcal capsular polysaccharide-protein conjugate vaccine according to the invention is a 20-valent immunogenic composition comprising capsular polysaccharides from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 6C / 6D, 7F, 9V, 11A, 12F, 14, 15A, 18C, 19A, 19F, 22F, 23A, 23F and 35B.
[0075] In yet another embodiment, the pneumococcal capsular polysaccharide-protein conjugate vaccine according to the invention is a 20-valent immunogenic composition comprising capsular polysaccharides from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 6C / 6D, 7F, 9V, 14, 15A, 15C, 18C, 19A, 19F, 23A, 23B, 23F, 24F and 35B.
[0076] In yet another embodiment, the pneumococcal capsular polysaccharide-protein conjugate vaccine according to the invention is a 24-valent immunogenic composition comprising capsular polysaccharides from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B.
[0077] In an embodiment, the invention provides a pneumococcal conjugate vaccine formulation comprising pneumococcal capsular polysaccharides conjugated to a carrier protein, wherein each polysaccharide is selected from Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F; and a preservative system comprising 2-phenoxyethanol at a concentration in the range of 0.1% to 0.6% and at least one other preservative selected from the group consisting of 0.005% to 0.3% m-cresol, 0.01% to 1% benzyl alcohol, 0.01% to 1% benzoic acid by weight of the vaccine formulation.
[0078] In yet another embodiment, the present invention provides a pneumococcal conjugate vaccine formulation comprising pneumococcal capsular polysaccharides conjugated to a carrier protein, wherein each polysaccharide is selected from Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F; and a preservative system comprising 2-phenoxyethanol at a concentration in the range of 0.1% to 0.5% and at least one other preservative selected from the group consisting of 0.005% to 0.3% m-cresol, 0.01% to 1% benzyl alcohol, 0.01% to 1% benzoic acid by weight of the vaccine formulation.
[0079] The carrier protein according to the invention is preferably a protein which is non-toxic and non-reactogenic and available in sufficient quantities and which is selected from PsaA, CRM 197 , inactivated bacterial toxins such as diphtheria toxoid (DT), tetanus toxoid (TT), pertussis toxoid, cholera toxoid, exotoxin A from Pseudomonas eruginosa, bacterial outer membrane proteins such as outer membrane complex C (OMPC), porins, transferrin binding protein, pneumolysin, PspA, C5a peptidase from group A or group B streptococci or Haemophilus influenzae protein D, ovalbumin, keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA) and protein derivatives of purified tuberculin (PPD) and combinations thereof. For example, some polysaccharides are conjugated to CRMs as carrier proteins. 197 And some polysaccharides are conjugated to PsaA or DT or TT and so on.
[0080] In still another embodiment, the present invention provides a multi-dose polysaccharide protein conjugate vaccine formulation comprising a preservative system comprising 2-phenoxyethanol at a concentration in the range of 0.1% to 0.5% and at least one other preservative selected from the group consisting of m-cresol, benzyl alcohol, phenol and benzoic acid, as well as a pharmaceutically acceptable vehicle and one or more pharmaceutically acceptable excipients / adjuvants.
[0081] In yet another embodiment, the present invention provides a conjugate vaccine formulation comprising a preservative system comprising 2-phenoxyethanol at a concentration in the range of 0.1% to 0.6% and at least one other preservative selected from the group consisting of 0.005% to 0.3% of m-cresol, 0.01% to 1% of benzyl alcohol, 0.01% to 1% of benzoic acid by weight of the vaccine formulation, and a pharmaceutically acceptable vehicle and one or more pharmaceutically acceptable excipients / adjuvants.
[0082] The composition according to the present invention can be conventionally manufactured. In particular, it can be formulated with pharmaceutically acceptable carriers, diluents or excipients, such as water, buffered saline, glycerol, propylene glycol and dextrose solution. In addition, the composition may include buffers such as sodium phosphate, potassium phosphate, sodium succinate, histidine, etc.; or stabilizers, polysorbate, MPLA (monophosphoryl lipid A), etc.; adjuvants such as aluminum compounds, such as aluminum hydroxide, aluminum phosphate or aluminum hydroxyphosphate, and freeze-drying excipients. In general, these ingredients / carriers can be selected according to the mode and route of administration and based on standard pharmaceutical practice.
[0083] The compositions of the present invention are formulated as multi-dose vials.
[0084] In still another embodiment, the present invention provides a method for preserving a vaccine formulation, the method comprising mixing a vaccine solution and one or more excipients such as an adjuvant, a diluent, a buffer or a surfactant with a preservative system comprising 2-phenoxyethanol at a concentration in the range of 0.1% to 0.5% and at least one other preservative selected from the group consisting of m-cresol, benzyl alcohol, phenol and benzoic acid to form a mixture of the vaccine solution and the preservative.
[0085] In a preferred embodiment, the present invention provides a vaccine formulation comprising a preservative system comprising 2-phenoxyethanol in a concentration range of 0.1% to 0.5% and at least one other preservative selected from the group consisting of 0.005% to 0.3% meta-cresol, 0.01% to 1% benzyl alcohol, 0.01% to 1% benzoic acid, and a pharmaceutically acceptable vehicle and one or more pharmaceutically acceptable excipients / adjuvants. Pharmaceutically acceptable excipients or adjuvants may be selected from adjuvants such as aluminum hydroxide, aluminum phosphate, surfactants such as polysorbate 20, polysorbate 80, poloxamer, vehicles, solvents or cosolvents such as soybean oil, PEG; stabilizers such as EDTA and may include antioxidants such as polyphenols, tocopherol polyethylene glycol succinate (TPGS). The pH of the vaccine formulation according to the present invention is adjusted to maintain between 4.0 and 8.0.
[0086] In another preferred embodiment, the present invention provides a vaccine formulation comprising 0.3% to 0.4% 2-PE and 0.1% to 0.3% m-cresol as preservatives and one or more pharmaceutically acceptable carriers or excipients.
[0087] In another preferred embodiment, the present invention provides a vaccine formulation comprising 0.1% to 0.4% 2-PE and 0.01% to 0.05% m-cresol as preservatives and one or more pharmaceutically acceptable carriers or excipients.
[0088] In another preferred embodiment, the present invention provides a 14-valent pneumococcal conjugate vaccine preparation comprising:
[0089] a) a capsular polysaccharide selected from Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F conjugated alone to a carrier protein selected from CRM197, pneumococcal surface protein A (PspA), pneumococcal adhesion protein (PsaA) or a combination thereof,
[0090] b) a preservative system comprising 0.1% to 0.4% 2-PE and 0.005% to 0.3% m-cresol and
[0091] c) one or more pharmaceutically acceptable carriers or excipients.
[0092] In a preferred embodiment, the present invention provides a 20-valent pneumococcal conjugate vaccine formulation comprising:
[0093] a) a capsular polysaccharide selected from Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 6C / 6D, 7F, 9V, 11A, 12F, 14, 15A, 18C, 19A, 19F, 22F, 23A, 23F and 35B conjugated alone to a carrier protein selected from CRM197, pneumococcal surface protein A (PspA), pneumococcal adhesion protein (PsaA) or a combination thereof,
[0094] b) a preservative system comprising 0.1% to 0.4% 2-PE and 0.005% to 0.1% m-cresol and
[0095] c) one or more pharmaceutically acceptable carriers or excipients.
[0096] In a preferred embodiment, the present invention provides a 24-valent pneumococcal conjugate vaccine formulation comprising:
[0097] a) a capsular polysaccharide selected from Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B conjugated alone to a carrier protein selected from CRM197, pneumococcal surface protein A (PspA), pneumococcal adhesion protein (PsaA) or a combination thereof,
[0098] b) a preservative system comprising 0.1% to 0.4% 2-PE and 0.005% to 0.1% m-cresol and
[0099] c) one or more pharmaceutically acceptable carriers or excipients.
[0100] The amount of pneumococcal conjugate in each vaccine dose is selected as an amount that induces an immune protective response without significant adverse effects. This amount may vary depending on the pneumococcal serotype. Each 0.5 mL dose is formulated to contain: 2 to 4 μg of each polysaccharide; approximately 30-70 μg of CRM197 carrier protein.
[0101] In another preferred embodiment, the present invention provides a conjugate vaccine formulation comprising a polysaccharide protein conjugate vaccine selected from the group consisting of a pneumococcal conjugate, a meningococcal conjugate, a typhoid conjugate, a paratyphoid or a Hib conjugate, and a preservative system comprising 0.1% to 0.4% 2-PE and 0.01% to 0.3% m-cresol and one or more pharmaceutically acceptable carriers or excipients.
[0102] In still another embodiment, the invention provides a pneumococcal conjugate vaccine formulation comprising pneumococcal capsular polysaccharides conjugated to a carrier protein, wherein each polysaccharide is selected from the group consisting of Streptococcus pneumoniae serotypes 1, 2, 3, 4, 5, 6A, 6B, 6C, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15A, 15B, 15C, 16F, 17F, 18C, 19F, 19A, 20A, 20B, 22F, 23A, 23B, 23F, 24B, 24F, 31, 33F, 34, 35B, 35F, 38, 39 and 45; and a preservative system comprising 2-phenoxyethanol in a concentration range of 0.1 to 0.5% and m-cresol in a concentration range of 0.01% to 0.3% by weight of the vaccine formulation.
[0103] The compositions of the present invention can be administered to a subject in need thereof by conventional routes used in the field of vaccines. For example, the compositions of the present invention can be administered systemically, such as parenterally (e.g., subcutaneously, intramuscularly, intradermally and / or intravenously) or mucosally (e.g., orally and / or nasally).
[0104] In some embodiments, the present invention also provides a method for inducing an immune response in a subject in need thereof. The method for inducing an immune response comprises administering an immunologically effective amount of a vaccine composition described herein to a subject in need thereof.
[0105] According to the methods of the present invention, the subject to which the compositions described herein are administered is a human, such as an infant (less than about 1 year old), a toddler (about 12 months to about 24 months old), a young child (about 2 years old to about 5 years old), a senior child (about 5 years old to about 13 years old), a teenager (about 13 years old to about 18 years old), an adult (about 18 years old to about 65 years old), or an elderly person (greater than about 65 years old).
[0106] In another preferred embodiment, the present invention provides an immunogenic composition of a pneumococcal conjugate vaccine comprising 0.1% to 0.4% 2-PE and 0.01% to 0.3% m-cresol and one or more pharmaceutically acceptable vehicles and one or more pharmaceutically acceptable excipients / adjuvants.
[0107] In another preferred embodiment, the present invention provides an immunogenic composition of a meningococcal conjugate vaccine comprising 0.3% to 0.4% 2-PE and 0.1% to 0.3% m-cresol and one or more pharmaceutically acceptable vehicles and one or more pharmaceutically acceptable excipients / adjuvants.
[0108] In another preferred embodiment, the present invention provides an immunogenic composition of a typhoid conjugate vaccine comprising 0.3% to 0.4% 2-PE and 0.1% to 0.3% m-cresol and one or more pharmaceutically acceptable vehicles and one or more pharmaceutically acceptable excipients / adjuvants.
[0109] In another preferred embodiment, the present invention provides an immunogenic composition of a paratyphoid vaccine, comprising 0.3% to 0.4% 2-PE and 0.1% to 0.3% m-cresol and one or more pharmaceutically acceptable vehicles and one or more pharmaceutically acceptable excipients / adjuvants.
[0110] In another preferred embodiment, the present invention provides an immunogenic composition of a Hib conjugate vaccine comprising 0.3% to 0.4% 2-PE and 0.1% to 0.3% m-cresol and one or more pharmaceutically acceptable vehicles and one or more pharmaceutically acceptable excipients / adjuvants.
[0111] Preservative efficacy in pharmaceuticals is often studied using challenge testing. In this test, the product is artificially contaminated with high concentrations of standard bacterial and fungal test strains. The rate and extent of reduction in inoculum viability over a specified period of time forms the basis for acceptance / rejection of preservative efficacy.
[0112] The efficacy of 2-phenoxyethanol (2-PE) and m-cresol preservative combinations having at least an effective dose when tested has shown strong bactericidal activity against Gram-positive bacteria, Gram-negative bacteria, yeasts, and fungi.
[0113] (manufactured by BTF Pty Ltd.) are small water-soluble spheres containing precise quantities of microorganisms, delivering unprecedented accuracy for quantitative microbiological quality control.
[0114] The compositions of the present invention may be prepared using conventional techniques involving appropriate dissolving and mixing of the ingredients to give the desired end product.
[0115] Example
[0116] The following examples are provided to illustrate the present disclosure and are for illustrative purposes only and should not be construed as limiting the scope of the present disclosure.
[0117] Example 1: Detailed Study of Preservative Selection and Efficacy Study
[0118] The aim of the study was to determine the lowest concentration of preservatives that could be used to formulate vaccines, specifically pneumococcal conjugate vaccines (PCVs), to which bacteria and fungi are susceptible. Two types of preservatives with different concentrations were selected for this study. Test cultures were prepared from glycerol aliquots of (manufactured by BTF Pty Ltd.)
[0119] In this study, the use of the lowest and effective dose of preservatives in polyvalent PCV was investigated. Microbiological content and preservative efficacy were investigated according to the United States Pharmacopeia (USP) 'USP29, General Chapter 51'. Microbial counts in test samples with different strengths of preservatives along with drug product (vaccine formulation) were examined from day 0 to day 35.
[0120] A single inoculum with an initial count of 1x10 5 Up to 1x10 7 An inoculum of 100 cells of microorganisms, which are the most common contaminants (Staphylococcus aureus, Pseudomonas aeruginosa, the yeast Candida albicans, Escherichia coli, and Aspergillus brasiliensis), was used to evaluate the strength of each preservative.
[0121] In the current study, LabTech TM Incubation of the test samples with the test organisms (Table 1) was performed in an incubator for a period of 35 days.
[0122] Table 1: Details of test organisms
[0123]
[0124]
[0125] Inoculum determination
[0126] If known amounts of different test organism populations are added to the test sample, initially, the samples are diluted with sterile saline solution from 10 -1 Up to 10 -8 Serial dilutions of 1 ml frozen vial contents were checked for viability in the test culture. From the last 6 dilutions, 100 μL of the suspension was spread (pour plate method) on a suitable culture medium plate and incubated under optimal conditions. After the incubation period, the plate was observed and colonies were counted to find the CFU / mL of each test organism.
[0127] Table 2: Incubation details
[0128]
[0129] Based on the results obtained in the inoculum determination, the final volume of inoculum added to the formulation was calculated to maintain the desired final concentration according to the pharmacopoeial requirements.
[0130] Since the target product for which the effective dose of the antimicrobial substance is to be determined is to fall within Category-1 according to USP 29 General Parts Chapter 51, the volume of the suspension inoculum used is between 0.5% and 1.0% of the product volume.
[0131] Table 3: Details of the volume of inoculum to be added
[0132]
[0133] Sample preparation and inoculum addition
[0134] Initially, formulations without drug product were prepared to test a wide range of concentrations of preservatives alone or in combination. Based on the results, experiments were designed with preservatives alone or in combination with drug product at lower concentration ranges.
[0135] The concentrations of the test microorganisms added to the product were such that the final concentration of the test preparation after inoculation met all pharmacopoeial requirements. These details are listed in Table 4a and Table 4b.
[0136] Table 4a: Formulation Details (without drug product)
[0137]
[0138] Table 4b: Formulation Details (with drug product)
[0139]
[0140] Further based on the results of the inoculum determination process, known concentrations of cells are inoculated into the formulation with drug product samples. Post-inoculation samples are incubated at respective temperatures, collected and serially diluted at appropriate intervals to determine the number of viable cells present in each test sample.
[0141] Preservative efficacy tested against Staphylococcus aureus and Escherichia coli
[0142] In all samples tested, the formulation inoculated with S. aureus showed greater than 2 log reduction from the initial cell count and showed no growth for all compositions at day 35. The volume of the sample used was 100 μL.
[0143] Table 5: Test results of Staphylococcus aureus (NCTC10788)
[0144]
[0145] 2-PE = 2-phenoxyethanol; mC = m-cresol
[0146] Formulations inoculated with E. coli showed greater than 2 log reductions in samples containing 2-PE 3mg+mC 1mg, 2-PE 3mg+mC 0.5mg, 2-PE 3mg+mC 0.25mg, and 2-PE2mg+mC 0.5mg, as well as with 2-PE 3mg, mC 0.5mg, and 2-PE 3mg+mC 0.05mg; the preservative showed log reductions and few counts were observed on day 35.
[0147] Table 6: Test results of Escherichia coli (NCTC12923)
[0148]
[0149] 2-PE = 2-phenoxyethanol; mC = m-cresol
[0150] All preservative compositions used for S. aureus and E. coli met pharmacopoeial requirements.
[0151] Preservative efficacy tested against Pseudomonas aeruginosa and Candida albicans
[0152] Formulations inoculated with P. aeruginosa and C. albicans showed a reduction of greater than 2 logs from the initial cell count. P. aeruginosa showed no growth for all compositions except the formulation that did not contain any preservative (placebo). Starting from day 2, there was no growth in all preservative compositions.
[0153] Candida albicans showed no growth for all compositions from day 12. A decrease in cell count starting from day 2 was observed.
[0154] Table 7: Test results of Pseudomonas aeruginosa (NCTC12924)
[0155]
[0156] 2-PE = 2-phenoxyethanol; mC = m-cresol
[0157] Table 8: Test results of Candida albicans (NCPF3139)
[0158]
[0159]
[0160] 2-PE = 2-phenoxyethanol; mC = m-cresol
[0161] All preservative compositions used for P. aeruginosa and C. albicans met pharmacopoeial requirements.
[0162] Preservative efficacy tested against Aspergillus brasiliensis
[0163] Aspergillus brasiliensis showed no growth in all preservative compositions starting from day 12, except for the formulation not containing any preservative (placebo). A decrease in cell counts starting from day 2 was observed in all preservative compositions.
[0164] Table 9: Test results of Aspergillus brasiliensis (NCPF2275)
[0165]
[0166] 2-PE = 2-phenoxyethanol; mC = m-cresol
[0167] All preservative compositions used for A. brasiliensis met pharmacopoeial requirements.
[0168] Based on the results, it is apparent that the formulation containing the combined preservative of 0.05% (0.05 mg / ml) m-cresol and 0.2% (2 mg / ml) 2-phenoxyethanol was effective in preventing microbial growth in the final formulation.
[0169] Example 2: Formulation of 14-valent pneumococcal conjugate vaccine (without preservative)
[0170]
[0171]
[0172] Example 3: Formulation of 14-valent pneumococcal conjugate vaccine (with preservative)
[0173] Conjugate serotype Amount (μg) / dose (0.5ml) 1 2.2 3 2.2 4 2.2 5 2.2 6B 4.4 7F 2.2 9V 2.2 14 2.2 18C 2.2 19A 2.2 19F 2.2 22F 2.2 23F 2.2 33F 2.2 excipient Succinic acid 295 μg Elemental aluminum in the form of aluminum phosphate gel 0.5mg Poloxamer 188 1000μg 2-Phenoxyethanol 3mg m-Cresol 1mg 0.9% sodium chloride solution (w / v) qs
[0174] Given below are the process steps involved in making the formulation of the 14-valent pneumococcal conjugate vaccine.
[0175] Take a portion of the saline and then add a large amount of pneumococcal monovalent conjugate (PnMBC). Mix it for a few minutes to obtain uniformity, then slowly add a batch of 10% sterile poloxamer 188 solution, and mix again for about 5 minutes to achieve uniformity. Subsequently add a sterile filtered succinic acid stock solution, then add a 2-phenoxyethanol stock solution and a meta-cresol stock solution. Mix for a few minutes, and add a batch of aluminum phosphate gel to the blend under continuous stirring. After mixing for a few minutes, check the pH of the mixture and adjust it to ~5.8±0.2 using 1N NaOH, and make up the volume with the remaining portion of the saline. Continue to further blend for 2 hours at 200±50RPM for adsorption to obtain the final amount.
[0176] After sampling, both bulk vaccine batches were aseptically and individually filled into vials in a laminar airflow unit, the vials required for testing were sampled, and the remaining vials were stored in a 2-8°C chamber.
[0177] Example 4: Formulation of hexavalent vaccine
[0178]
[0179] Given below are the process steps involved in making the hexavalent formulation described above:
[0180] i. HepB antigen, diphtheria toxoid and tetanus toxoid were added to a blending vessel containing aluminum phosphate and the mixture was stirred for 12-16 hours,
[0181] ii. The pH of wP is adjusted to 6.8-7.2 and added to the DT-HepB mixture obtained in step (i), and the pH is adjusted to 6.2-6.5,
[0182] iii. To the above DTwP-Hep B mixture, add S19 IPV bulk antigen, followed by saline solution,
[0183] iv. Add the solution of 2-PE and cool the mixture at 2-8°C,
[0184] v. adding HibTT to the mixture obtained in step (iv),
[0185] vi. Adjust volume with normal saline solution and place solution in separate containers.
[0186] Example 5: Formulation of 14-valent pneumococcal conjugate vaccine (with preservative)
[0187]
[0188]
[0189] Example 6: Formulation of 14-valent pneumococcal conjugate vaccine (with preservative)
[0190] Conjugate serotype Amount (μg) / dose (0.5ml) 1 2.2 3 2.2 4 2.2 5 2.2 6B 4.4 7F 2.2 9V 2.2 14 2.2 18C 2.2 19A 2.2 19F 2.2 22F 2.2 23F 2.2 33F 2.2 excipient Succinic acid 295 μg Elemental aluminum in the form of aluminum phosphate gel 0.5mg Polysorbate 80 100 μg 2-Phenoxyethanol 3mg benzoic acid 2mg 0.9% sodium chloride solution (w / v) qs
[0191] Example 7: Formulation of 14-valent pneumococcal conjugate vaccine (with preservative)
[0192] Conjugate serotype Amount (μg) / dose (0.5ml) 1 2.2 3 2.2 4 2.2 5 2.2 6B 4.4 7F 2.2 9V 2.2 14 2.2 18C 2.2 19A 2.2 19F 2.2 22F 2.2 23F 2.2 33F 2.2 excipient Succinic acid 295 μg Elemental aluminum in the form of aluminum phosphate gel 0.5mg Poloxamer 188 1000μg 2-Phenoxyethanol 3mg Phenolic acid 2mg 0.9% sodium chloride solution (w / v) qs
[0193] Example 8: Immunization of rabbits with a preservative-containing formulation of PCV
[0194] To find out if formulations containing preservative combinations had any negative effects on serum antibody titers, vaccine formulations containing two preservatives were prepared (Example 2). Another formulation without any preservatives but containing exactly the same excipients was prepared as a 'control' (Example 3). These polysaccharide conjugates were adsorbed onto aluminum phosphate gels and key vaccine quality attributes were assessed following pharmacopoeial guidelines.
[0195] Healthy rabbits, each weighing 1.5 to 2 kg, were bred and raised in a closed facility. Rabbits were immunized with the above formulations. Groups of 7 rabbits were immunized with the formulations of Example 2 or Example 3 on Day 1, Day 15, and Day 29. Blood samples were collected on Day 0 (pre-immunization), Day 15 (test bleeding), and Day 36 (final bleeding). Rabbit sera collected on Day 0 (PD1) and Day 40 (PD3) were analyzed for serotype-specific immune responses using ELISA. ELISA was performed according to the protocol recommended by WHO.
[0196]
[0197] Potency Assessment
[0198] Antibody titers in immunized animals were assigned as the reciprocal of the dilution factor, which showed an OD 450nm =Twice the pre-immune titer (approximately 0.2 OD). The serum antibody titer of each animal (n=7) was plotted on a logarithmic scale (on the y-axis) using MedCalc. The error bars represent the variance at the 95% confidence interval (CI). The midpoint in the error bar represents the group mean serum antibody titer.
[0199] A guide to reading the diagram is given below, which describes how the diagram is laid out ( Figure 1 ). Briefly, the x-axis legend contains the formulation ID, the bleed analyzed, and the serotype tested. For example, PI_ST1 means the serum antibody titer against serotype 1 in rabbits immunized with the formulation disclosed in Example 2 at the pre-immunization bleed, PD3_ST1 means the serum antibody titer against serotype 1 in rabbits immunized with the formulation disclosed in Example 2 at the post-dose 3 bleed, PD3_ST22F means the serum antibody titer against serotype 22F in rabbits immunized with the formulation disclosed in Example 2 at the post-dose 3 bleed, and so on ( Figure 2A A and B). This is usually expected to be background titers in rabbits before immunization. However, after the third dose of immunization, serum antibody titers increased several fold, indicating a strong and specific immune response in the immunized animals.
[0200] Similarly, Figure 3API_ST1 in PD3 and B represents the serum antibody titer against serotype 1 in rabbits immunized with the formulation disclosed in Example 3 at the time of bleeding before immunization, PD3_ST1 represents the serum antibody titer against serotype 1 in rabbits immunized with the formulation disclosed in Example 3 at the time of bleeding after dose 3, PD3_ST22F represents the serum antibody titer against serotype 22F in rabbits immunized with the formulation disclosed in Example 3 at the time of bleeding after dose 3, etc. It was observed that the serum antibody titer in rabbits immunized with the formulation described in Example 3 was similar to the serum antibody titer observed in rabbits immunized with the formulation disclosed in Example 2. Therefore, the data herein indicate that the presence of the preservative composition has no negative impact on the immunogenicity of the vaccine formulation.
[0201] The preservative concentrations selected to test the immune response were 0.6 mg / ml of 2-PE and 0.2 mg / mL of m-cresol. As shown in the figure, at this concentration of preservative, there was no inhibitory effect on the immune response in rabbits, and concentrations below this concentration were not expected to have any negative effects on the immune response.
Claims
1. A vaccine formulation comprising an antigen and a preservative system consisting of 2-phenoxyethanol and m-cresol at a concentration ranging from 0.1% to 0.4%, wherein the concentration of m-cresol is in the range of 0.01% to 0.3%.
2. The vaccine formulation of claim 1, comprising one or more pharmaceutically acceptable carriers.
3. The vaccine formulation of claim 1, wherein the vaccine formulation is a monovalent vaccine formulation or a multivalent combination vaccine formulation.
4. The vaccine formulation of claim 3, wherein the monovalent vaccine formulation comprises an antigen selected from or isolated from the group consisting of Streptococcus pneumoniae, Neisseria meningitidis, Salmonella typhi, Salmonella paratyphi, Haemophilus influenzae, Corynebacterium diphtheriae, Bacterium pertussis, Clostridium tetani, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, inactivated Japanese encephalitis virus, rabies virus, and inactivated poliovirus.
5. The vaccine formulation of claim 3, wherein the monovalent vaccine formulation comprises an antigen selected from or isolated from the group consisting of pneumococcal capsular polysaccharide, Neisseria meningitidis A, Neisseria meningitidis C, Neisseria meningitidis W-135, Neisseria meningitidis X, Neisseria meningitidis Y, Salmonella Typhi Vi, Salmonella Paratyphi O:2, Hib-PRP, Diphtheria Toxoid-DT, Bacteria pertussis wP / aP, and Tetanus Toxoid.
6. The vaccine formulation of claim 3, wherein the multivalent combination vaccine formulation is selected from the group consisting of a bivalent vaccine, a trivalent vaccine, a quadrivalent vaccine, a pentavalent vaccine, a hexavalent vaccine, and a pneumococcal conjugate vaccine.
7. The vaccine formulation of claim 6, wherein the bivalent vaccine is selected from the group consisting of Td vaccine, Vi:O2 conjugate and MR; and, wherein the trivalent vaccine is selected from the group consisting of DTwP, Vi:O2-HepA, and MMR; and, wherein the quadrivalent vaccine is selected from the group consisting of DTwP-Hib, DTaP-Hib, DTwP-IPV, DTwP-HepB, ACW-135Y; and, wherein the pentavalent vaccine is selected from the group consisting of DTwPHib-HepB and DTaPHib-HepB; and, wherein the hexavalent vaccine is selected from the group consisting of DTwPHib-HepB-IPV and DTaPHib-HepB-IPV.
8. The vaccine formulation of claim 6, wherein the pneumococcal conjugate vaccine comprises one or more pneumococcal capsular polysaccharide protein conjugates, the preservative system of claim 1 and, optionally, one or more pharmaceutically acceptable carriers.
9. The vaccine formulation of claim 8, wherein the pneumococcal capsular polysaccharide protein conjugate comprises a pneumococcal capsular polysaccharide selected from the group consisting of serotypes 1, 2, 3, 4, 5, 6A, 6B, 6C, 6D, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15A, 15B, 15C, 16F, 17F, 18C, 19F, 19A, 20A, 20B, 22F, 23A, 23B, 23F, 24B, 24F, 31, 33F, 34, 35B, 35F, 38, 39, and 45; and, wherein each polysaccharide is conjugated to a 197 and a carrier protein of an inactivated bacterial toxin selected from the group consisting of diphtheria toxoid (DT), tetanus toxoid (TT), pertussis toxoid, cholera toxoid and Haemophilus influenzae protein D or a combination thereof.
10. The vaccine formulation of claim 9, wherein each pneumococcal capsular polysaccharide is selected from S. pneumoniae serotypes 1, 2, 3, 4, 5, 6A, 6B, 6C, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15A, 15B, 15C, 16F, 17F, 18C, 19F, 19A, 20A, 20B, 22F, 23A, 23B, 23F, 24B, 24F, 31, 33F, 34, 35B, 35F, 38, 39 and 45 conjugated to a carrier protein, and wherein the vaccine formulation comprises one or more pharmaceutically acceptable carriers or excipients.
11. The vaccine formulation of claim 10, wherein the vaccine formulation is selected from one of the following: a. a 14-valent pneumococcal capsular polysaccharide protein conjugate vaccine comprising capsular polysaccharides from Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F, b. a 20-valent pneumococcal capsular polysaccharide protein conjugate vaccine comprising capsular polysaccharides from Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 6C / 6D, 7F, 9V, 11A, 12F, 14, 15A, 18C, 19A, 19F, 22F, 23A, 23F and 35B, c. a 20-valent pneumococcal capsular polysaccharide protein conjugate vaccine comprising capsular polysaccharides from Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 6C / 6D, 7F, 9V, 14, 15A, 15C, 18C, 19A, 19F, 23A, 23B, 23F, 24F and 35B, d. A 24-valent pneumococcal capsular polysaccharide-protein conjugate vaccine comprising capsular polysaccharides from Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B.
12. Use of the preservative system in the vaccine preparation of claim 1 to prevent bacterial or fungal contamination in the vaccine preparation.
Citation Information
Patent Citations
Vaccine formulation with a preservative
US20040258700A1
Novel formulations which mitigate agitation-induced aggregation of immunogenic compositions
US20130273098A1
Preservatives for vaccines
US6790445B1
Vaccine formulations
US9095567B2
Polyvalent streptococcus pneumoniae vaccine composition
WO2018169303A1
